Vosoritide, sold under the brand name Voxzogo, is a medication used for the treatment of achondroplasia, a genetic condition that causes severely short...
19 KB (1,329 words) - 15:13, 7 September 2024
Treatments include small molecule therapy with a C-natriuretic peptide analog (vosoritide), approved to improve growth velocity in children with achondroplasia...
47 KB (4,410 words) - 00:18, 19 October 2024
ranelate M05BX04 Denosumab M05BX05 Burosumab M05BX06 Romosozumab M05BX07 Vosoritide M05BX08 Menatetrenone M05BX53 Strontium ranelate and colecalciferol "ATC...
2 KB (276 words) - 09:14, 31 December 2022
Daniel (December 2021). "Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase...
27 KB (2,785 words) - 05:19, 10 October 2024
2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia. In 2012, BioMarin acquired...
19 KB (1,679 words) - 14:00, 30 August 2024
a year after originally rejecting that status. 15 November: The drug Vosoritide, used to treat achondroplasia, is introduced in Georgia after months of...
101 KB (9,779 words) - 23:10, 15 September 2024